Safety and Efficacy of Iparomlimab and Tuvonralimab in Combination with Gemcitabine and Cisplatin As First-Line Treatment for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Trial (DUBHE-N-302).